The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate of 10.3% across the seven major markets (7MM: US, 5EU [France, Germany, Italy, Spain, UK], and Japan), according to leading data and analytics company GlobalData’s recently published report, Endometriosis: Seven-Market Drug Forecast and Market Analysis. This growth over the forecast period is primarily driven by the anticipated launch of three pipeline drugs: Kissei Pharmaceutical’s Yselty, which is already available in the 5EU and expected to enter the US and Japanese markets; Hope Medicine’s HMI-115, set to launch in the US; and Fuji Pharma’s Alyssa, projected for release in Japan.
Although newer gonadotropin-releasing hormone (GnRH) antagonists are gaining popularity due to improved safety profiles, AstraZeneca and Pfizer are likely to retain a strong presence in the market. Bayer is another key player, particularly known for its progestin-based therapy Visanne, which is widely used for the long-term management of endometriosis symptoms. Myfembree/Ryeqo, developed by Myovant Sciences in collaboration with Sumitomo Pharma, is an oral GnRH antagonist that is well-positioned for success. Unlike traditional GnRH agonists, Ryeqo has a favourable safety profile, causing fewer side effects such as hot flashes and bone mineral density loss. Its once-daily dosing improves patient adherence and offers a more attractive long-term treatment option. With recent approval in the US and the 5EU, Myfembree/Ryeqo is strengthening its presence in the global endometriosis treatment landscape.
Among the 7MM countries included in this forecast, the US stands out as the largest contributor to the endometriosis market, representing 68.3% of total sales in 2024 and projected to account for 88.4% by 2034. This dominant position is largely attributed to the higher pricing of therapeutics in the US compared to the other six markets, as well as a larger endometriosis patient population.
The figures below summarise the projected growth in the endometriosis market across the 7MM from 2024 to 2034.
Major drivers of the endometriosis market growth during the forecast period are:
- The anticipated launch of Kissei Pharmaceutical’s Yselty, currently available in the 5EU and under development for the US and Japanese markets.
- The expected launch of Hope Medicine’s HMI-115 in the US and Fuji Pharma’s Alyssa in Japan.
- Continual improvements with disease awareness, leading to an increase in diagnoses.
- Improvements in noninvasive diagnostic methods such as the utilisation of biomarkers, which should further increase the number of early diagnoses.
Major barriers will restrict the growth of the endometriosis market during the forecast period:
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData- The endometriosis market boasts many off-label medications and is still highly genericised, presenting a stiff barrier for novel therapy entrants.
- The shrinking female population aged 12-54 years in the 5EU and Japan will dampen the extent of growth in diagnosed endometriosis cases.
